NASDAQ
KRYS

Krystal Biotech Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Krystal Biotech Inc Stock Price

Vitals

Today's Low:
$126.75
Today's High:
$132.43
Open Price:
$128.07
52W Low:
$61.11
52W High:
$132.43
Prev. Close:
$128.44
Volume:
261451

Company Statistics

Market Cap.:
$3.60 billion
Book Value:
23.346
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-13.71%
Return on Equity TTM:
-23.16%

Company Profile

Krystal Biotech Inc had its IPO on 2017-09-20 under the ticker symbol KRYS.

The company operates in the Healthcare sector and Biotechnology industry. Krystal Biotech Inc has a staff strength of 210 employees.

Stock update

Shares of Krystal Biotech Inc opened at $128.07 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $126.75 - $132.43, and closed at $127.34.

This is a -0.86% slip from the previous day's closing price.

A total volume of 261,451 shares were traded at the close of the day’s session.

In the last one week, shares of Krystal Biotech Inc have increased by +0.86%.

Krystal Biotech Inc's Key Ratios

Krystal Biotech Inc has a market cap of $3.60 billion, indicating a price to book ratio of 3.3819 and a price to sales ratio of 0.

In the last 12-months Krystal Biotech Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-137116992. The EBITDA ratio measures Krystal Biotech Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Krystal Biotech Inc’s operating margin was 0% while its return on assets stood at -13.71% with a return of equity of -23.16%.

In Q2, Krystal Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Krystal Biotech Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-5.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Krystal Biotech Inc’s profitability.

Krystal Biotech Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -11.4587. Its price to sales ratio in the trailing 12-months stood at 0.

Krystal Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$684.03 million
Total Liabilities
$23.90 million
Operating Cash Flow
$-15957000.00
Capital Expenditure
$2.79 million
Dividend Payout Ratio
0%

Krystal Biotech Inc ended 2024 with $684.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $684.03 million while shareholder equity stood at $653.11 million.

Krystal Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $23.90 million in other current liabilities, in common stock, $-359266000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $275.88 million and cash and short-term investments were $477.52 million. The company’s total short-term debt was $1,529,000 while long-term debt stood at $0.

Krystal Biotech Inc’s total current assets stands at $484.00 million while long-term investments were $28.41 million and short-term investments were $201.64 million. Its net receivables were $0 compared to accounts payable of $4.45 million and inventory worth $0.

In 2024, Krystal Biotech Inc's operating cash flow was $-15957000.00 while its capital expenditure stood at $2.79 million.

Comparatively, Krystal Biotech Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$127.34
52-Week High
$132.43
52-Week Low
$61.11
Analyst Target Price
$148.57

Krystal Biotech Inc stock is currently trading at $127.34 per share. It touched a 52-week high of $132.43 and a 52-week low of $132.43. Analysts tracking the stock have a 12-month average target price of $148.57.

Its 50-day moving average was $123.11 and 200-day moving average was $96.73 The short ratio stood at 5.68 indicating a short percent outstanding of 0%.

Around 1395.5% of the company’s stock are held by insiders while 8054.8% are held by institutions.

Frequently Asked Questions About Krystal Biotech Inc

The stock symbol (also called stock or share ticker) of Krystal Biotech Inc is KRYS

The IPO of Krystal Biotech Inc took place on 2017-09-20

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Tata Coffee Limited (TATACOFFEE)
$252.55
-0.7
-0.28%
$22.66
-1.19
-4.99%
$7.15
-0.06
-0.83%
$13.44
0.38
+2.91%
$26.6
0.32
+1.22%
$39.61
-0.58
-1.44%
$161.7
-3.3
-2%
$398.95
-17.7
-4.25%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Address

2100 Wharton Street, Pittsburgh, PA, United States, 15203